Biogen Idec Inc (BIIB): Biogen Idec Management Discusses Q3 2013 Results …Seeking AlphaAlso in mid-2014, we look forward to seeing Phase III data for daclizumab in relapsing-remitting MS. Data from the daclizumab Phase IIb registrational study point …
|
Accelerated growth for AbbVie’s Humira lifts 3rd-quarter results above expectation
The Pharma Letter AbbVie’s partnership with Biogen Idec (Nasdaq: BIIB) on daclizumab also looks promising. The drug targets treatment of patients with relapsed or remitting multiple sclerosis. Daclizumab is currently in a late-stage study. AbbVie and Biogen expect that … |
|
AbbVie Inc (ABBV): AbbVie’s CEO Discusses Q3 2013 Results – Earnings Call …
Seeking Alpha In addition to assets currently in late-stage such as HCV, daclizumab, elagolix, (inaudible) and elotuzumab were on the cusp of transitioning several additional programs in the Phase 3 development, including but not limited to ABT-199 per CLL and ABT … |
Jutia Group |
What’s Behind AbbVie’s Rocking Q3 Earnings
DailyFinance AbbVie’s partnership with Biogen Idec on daclizumab also looks promising. The drug targets treatment of patients with relapsed or remitting multiple sclerosis. Daclizumab is currently in a late-stage study. AbbVie and Biogen expect that study to wrap … AbbVie Inc (ABBV): AbbVie’s CEO Discusses Q3 2013 Results – Earnings Call …Seeking Alpha AbbVie Reports Third-Quarter 2013 Financial ResultsMarketWatch |
Jutia Group |
What’s Behind AbbVie’s Rocking Q3 Earnings
Motley Fool AbbVie’s partnership with Biogen Idec (NASDAQ: BIIB ) on daclizumab also looks promising. The drug targets treatment of patients with relapsed or remitting multiple sclerosis. Daclizumab is currently in a late-stage study. AbbVie and Biogen expect that … AbbVie Inc (ABBV): AbbVie’s CEO Discusses Q3 2013 Results – Earnings Call …Seeking Alpha AbbVie Reports Third-Quarter 2013 Financial ResultsMarketWatch |
ABBVIE INC : AbbVie Reports Third-Quarter 2013 Financial Results4-traders (press release)With partner Biogen Idec, AbbVie presented data from sub-analyses of the Phase 2 SELECT and SELECTION studies evaluating daclizumab. Daclizumab High-Yield Process …
AbbVie Reports Third-Quarter 2013 Financial ResultsWall Street JournalWith partner Biogen Idec, AbbVie presented data from sub-analyses of the Phase 2 SELECT and SELECTION studies evaluating daclizumab. Daclizumab High-Yield Process (DAC HYP) is being …
AbbVie Reports Third-Quarter 2013 Financial ResultsPR Newswire (press release)With partner Biogen Idec, AbbVie presented data from sub-analyses of the Phase 2 SELECT and SELECTION studies evaluating daclizumab. Daclizumab High-Yield Process (DAC HYP) i…
AbbVie Reports Third-Quarter 2013 Financial ResultsMarketWatchWith partner Biogen Idec, AbbVie presented data from sub-analyses of the Phase 2 SELECT and SELECTION studies evaluating daclizumab. Daclizumab High-Yield Process (DAC HYP) is being develope…
|
15 neue Wirkstoffe angekündigt
Ärzte Zeitung in Phase II ein Alpha-7-Nikotin-Rezeptoragonist (ABT-126) gegen Alzheimer und Schizophrenie getestet, sowie. • zusammen mit einem Partnerunternehmen in Phase III der immunsuppressiv wirkenden Antikörper Daclizumab gegen Multiple Sklerose. |